Deregulation of calcium homeostasis mediates secreted α-synuclein-induced neurotoxicity

Neurobiol Aging. 2013 Dec;34(12):2853-65. doi: 10.1016/j.neurobiolaging.2013.06.006. Epub 2013 Jul 25.

Abstract

α-Synuclein (AS) plays a crucial role in Parkinson's disease pathogenesis. AS is normally secreted from neuronal cells and can thus exert paracrine effects. We have previously demonstrated that naturally secreted AS species, derived from SH-SY5Y cells inducibly overexpressing human wild type AS, can be toxic to recipient neuronal cells. In the current study, we show that application of secreted AS alters membrane fluidity and increases calcium (Ca2+) entry. This influx is reduced on pharmacological inhibition of voltage-operated Ca2+ channels. Although no change in free cytosolic Ca2+ levels is observed, a significantly increased mitochondrial Ca2+ sequestration is found in recipient cells. Application of voltage-operated Ca2+ channel blockers or Ca2+ chelators abolishes AS-mediated toxicity. AS-treated cells exhibit increased calpain activation, and calpain inhibition greatly alleviates the observed toxicity. Collectively, our data suggest that secreted AS exerts toxicity through engagement, at least in part, of the Ca2+ homeostatic machinery. Therefore, manipulating Ca2+ signaling pathways might represent a potential therapeutic strategy for Parkinson's disease.

Keywords: Alpha-synuclein; Calpains; Exosomes; Membrane fluidity; Mitochondria; Neurodegeneration; Parkinson's disease; Secretion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium / metabolism*
  • Calcium / physiology*
  • Calcium Channel Blockers / pharmacology
  • Calcium Channel Blockers / therapeutic use
  • Calcium Signaling / drug effects
  • Calcium Signaling / physiology
  • Cells, Cultured
  • Chelating Agents / pharmacology
  • Chelating Agents / therapeutic use
  • Homeostasis / drug effects*
  • Humans
  • Membrane Fluidity / drug effects
  • Molecular Targeted Therapy
  • Neurons / drug effects*
  • Neurons / metabolism*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / genetics*
  • alpha-Synuclein / metabolism
  • alpha-Synuclein / toxicity*

Substances

  • Calcium Channel Blockers
  • Chelating Agents
  • alpha-Synuclein
  • Calcium